Literature DB >> 9427226

Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM).

J A Cohen1, B W Jeffers, D Faldut, M Marcoux, R W Schrier.   

Abstract

Identification of risk factors for development of diabetic sensorimotor peripheral neuropathy (DSPN) and diabetic autonomic neuropathy (DNA) may help to prevent or modify these complications. The ABCD Trial, a prospective study of diabetic complications, has identified risk factors of the presence and staging of peripheral neuropathy based on neurological symptom scores, neurological disability scores, autonomic function testing and quantitative sensory examination. DSPN is independently associated with diabetes duration [odds ratio (OR) = 1.5 per 10 years], body weight (OR = 1.1 per 5 kg), age (OR = 1.8 per 10 years), retinopathy (OR = 2.3), overt albuminuria (OR = 2.5), height (OR = 1.2 per 10 cm), duration of hypertension (OR = 1.1 per 10 years), insulin use (OR = 1.4), and race/ethnicity [African American vs. non-Hispanic white (OR = 0.4) and Hispanic vs. non-Hispanic white (OR = 0.8)]. DAN is independently associated with diabetes duration (OR = 1.2 per 10 years), body weight (OR = 1.1 per 5 kg), glycosylated hemoglobin (OR = 1.1 per 2.5%), overt albuminuria (OR = 1.6), and retinopathy (OR = 1.8).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427226     DOI: 10.1002/(sici)1097-4598(199801)21:1<72::aid-mus10>3.0.co;2-2

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  23 in total

Review 1.  Risk factors for diabetic neuropathy and foot ulceration.

Authors:  A Adler
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

2.  Sensory nerve-mediated and nitric oxide-dependent cutaneous vasodilation in normotensive and prehypertensive non-Hispanic blacks and whites.

Authors:  Brett J Wong; Casey G Turner; James T Miller; Demetria C Walker; Yesser Sebeh; Matthew J Hayat; Jeffrey S Otis; Arshed A Quyyumi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-06-19       Impact factor: 4.733

3.  Diabetic peripheral neuropathy: an update on pathogenesis and management.

Authors:  Betul M Gundogdu
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

4.  Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation.

Authors:  Amanda Peltier; A Gordon Smith; James W Russell; Kiran Sheikh; Billie Bixby; James Howard; Jonathan Goldstein; Yanna Song; Lily Wang; Eva L Feldman; J Robinson Singleton
Journal:  Muscle Nerve       Date:  2009-04       Impact factor: 3.217

Review 5.  The prevalence of diabetic neuropathy according to ethnicity.

Authors:  Jay M Sosenko
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

6.  Treatment of diabetic sensory polyneuropathy.

Authors:  Lindsay Zilliox; James W Russell
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

7.  Peripheral insensate neuropathy-is height a risk factor?

Authors:  G S Sharath Kote; Ajay N Bhat; Thajuddeen K; Mohammed H Ismail; Abhishek Gupta
Journal:  J Clin Diagn Res       Date:  2012-12-24

Review 8.  Neurologic complications of diabetes.

Authors:  Gerald A Charnogursky; Nicholas V Emanuele; Mary Ann Emanuele
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

Review 9.  Diabetic neuropathy: mechanisms to management.

Authors:  James L Edwards; Andrea M Vincent; Hsinlin T Cheng; Eva L Feldman
Journal:  Pharmacol Ther       Date:  2008-06-13       Impact factor: 12.310

Review 10.  Combined pharmacologic/nonpharmacologic intervention in individuals at high risk of developing type 2 diabetes: pro pharmacologic therapy.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.